Paul Herzich
Direttore Tecnico/Scientifico/R&S presso SOLID BIOSCIENCES INC.
Patrimonio netto: 51 428 $ in data 30/04/2024
Profilo
Paul Herzich is currently the Chief Technology Officer at Solid Biosciences, Inc. Prior to this, he held positions as Director-CGMP & Senior Manager at Bamboo Therapeutics, Inc., Senior Director-Manufacturing at LogicBio Therapeutics, Inc., Vice President-CMC at BridgeBio Pharma, Inc., and Chief Technology Officer at Aavantibio, Inc. He also served as Head-TD Manufacturing at Csl Seqirus from 2007 to 2015.
Dr. Herzich received an undergraduate degree from Rutgers State University of New Jersey and an MBA from Poole College of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
SOLID BIOSCIENCES INC.
0.02% | 13/02/2024 | 6 022 ( 0.02% ) | 51 428 $ | 30/04/2024 |
Posizioni attive di Paul Herzich
| Società | Posizione | Inizio |
|---|---|---|
| SOLID BIOSCIENCES INC. | Direttore Tecnico/Scientifico/R&S | 01/12/2022 |
Precedenti posizioni note di Paul Herzich
| Società | Posizione | Fine |
|---|---|---|
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Direttore Tecnico/Scientifico/R&S | 01/12/2022 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01/04/2021 |
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2019 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 01/01/2018 |
| Csl Seqirus | Corporate Officer/Principal | 01/07/2015 |
Formazione di Paul Herzich
| Poole College of Management | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
| Csl Seqirus |
- Borsa valori
- Insiders
- Paul Herzich